YD Bio Limited Ordinary Shares (YDES) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $276M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerYD Bio Limited Ordinary Shares (YDES) trades at $3.90 with MoonshotScore 56/100 (Grade B). YD Bio Limited Ordinary Shares is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. They focus on cancer prevention medical diagnostics and exosome-based therapeutics.
Price as of Sep 11, 2026 · Last analyzed: Sep 10, 2026YD Bio Limited Ordinary Shares is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. They focus on cancer prevention medical diagnostics and exosome-based therapeutics.
Analyst Coverage for YDES: YDES does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates YDES against sector peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
YDES: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Strongest side: Financial Safety (9/10, Strong). Weakest side: Growth Durability (2/10, Weak).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
YD Bio Limited Ordinary Shares Company Overview
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scored on 92% of our measures
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Why 56?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.78 Return on equity (Business Quality)
- +0.60 Bankruptcy-risk score (Financial Strength)
- +0.26 Volatility vs the market (Financial Strength)
What is holding it back
- -0.48 Share dilution (Growth)
- -0.33 Operating income growth (Growth)
- -0.21 Free cash flow growth (Growth)
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
YDES Current Price & Trading Activity
As of the latest market session, shares of YD Bio Limited Ordinary Shares (YDES) are priced at $3.90, down 0.64% on the day.
The stock has a trading volume of 633.2K shares, which provides insight into market interest and liquidity for this security. Based on the current price and market capitalization, YDES has approximately 71 million shares outstanding.
Company Profile: YD Bio Limited Ordinary Shares
YD Bio Limited Ordinary Shares (YDES) is a publicly traded company. With a market capitalization of $276M, it is classified as a micro-cap stock, reflecting its relative size within the broader equity market.
Analyst Coverage for YDES
YDES does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model scores YDES on quantitative fundamentals — growth, financial health, valuation, and momentum — relative to sector peers and assigns a mixed fundamental profile based on the underlying data. Investors monitoring YDES should weigh peer-relative metrics and sector momentum more heavily until institutional coverage emerges.
YDES AI Analysis Score
Our AI scoring model rates YDES at 56/100, reflecting moderately positive indicators based on quantitative analysis. The composite draws on growth, financial health, valuation, and momentum data. Scores are updated regularly as new market data becomes available. Investors should use this score as one input alongside their own research and risk assessment.
Data sourced from Financial Modeling Prep, Yahoo Finance and SEC EDGAR. This content is generated from market data and is not financial advice. Past performance does not guarantee future results.
YDES Latest News
No recent news available for YDES.
YDES Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for YDES.
Price Targets
Wall Street price target analysis for YDES.
YDES MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. YDES scores 56/100 (Grade B): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
YD Bio Limited Ordinary Shares Stock: Key Questions Answered
What does the AI Score mean for YDES?
YDES holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is YDES a good stock?
Stock Expert AI does not rate YDES buy, sell or hold. YD Bio Limited Ordinary Shares carries a MoonshotScore of 56/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for YDES?
YD Bio Limited Ordinary Shares (YDES) holds an AI score of 56/100 (moderate). Not financial advice.
How frequently does YDES data refresh on this page?
YDES's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven YDES's recent stock price performance?
YD Bio Limited Ordinary Shares (YDES) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider YDES overvalued or undervalued right now?
YD Bio Limited Ordinary Shares (YDES) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of YDES?
Yes, most major brokerages offer fractional shares of YD Bio Limited Ordinary Shares (YDES) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track YDES's earnings and financial reports?
YD Bio Limited Ordinary Shares (YDES) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for YDES earnings announcements.
What should investors new to YDES understand first?
YD Bio Limited Ordinary Shares (YDES) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 56/100. With a market cap of $276.24M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.